Showing 2521-2530 of 5621 results for "".
- TearClear Announces Successful Completion of Pre-IND Meeting With the FDA for a Preservative-Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucomahttps://modernod.com/news/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma/2478608/TearClear announced successful completion of pre-IND (investigational new drug) meeting with the FDA regarding the development plan for the preservative-free multi-dose delivery of a proprietary latanoprost formulation, including the clinical study design for the registration
- When Coronavirus Vaccines Are Ready, Dentists, Optometrists May Give Shotshttps://modernod.com/news/when-coronavirus-vaccines-are-ready-dentists-optometrists-may-give-shots/2478599/With multiple COVID-19 vaccines rapidly heading toward approval, optometrists and dentists are pushing for the authority to immunize patients during routine eye exams and dental cleanings. These medical professionals say their help will be needed to distribute the vaccines
- Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027https://modernod.com/news/report-dry-eye-treatment-devices-market-size-worth-400-8-million-by-2027/2478591/The global dry eye treatment devices market size is estimated to reach US$400.8 million by 2027, expanding at a CAGR of 6.4%, according to a new report by Grand View Research, Inc. The increasing demand for targeted, noninvasive, faster, and patient compliant treatment methods to alleviate dry ey
- Doctors Report Patients’ Health Declining Due to Delayed or Inaccessible Care During COVID-19 Pandemichttps://modernod.com/news/doctors-report-patients-health-declining-due-to-delayed-or-inaccessible-care-during-covid-19-pandemic/2478581/Patients’ overall health continues to suffer due to the pandemic, with the majority of primary care physicians reporting that their patients’ mental health has declined during the past 8 months, according to a FierceHealthcare
- Azar Expects 40M COVID-19 Vaccine Doses Ready to Distribute By End of Decemberhttps://modernod.com/news/azar-expects-40m-covid-19-vaccine-doses-ready-to-distribute-by-end-of-december/2478576/Department of Health and Human Services Secretary Alex Azar expects 40 million doses of Pfizer and Moderna’s COVID-19 vaccines will be ready for distribution by the end of December as providers must gear up now to allocate the doses, according to a FierceHealthcare
- Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelineshttps://modernod.com/news/hydrus-microstent-receives-highest-designation-of-any-migs-device-as-part-of-aao-treatment-guidelines/2478570/Ivantis, developer of the novel Hydrus Microstent MIGS device, announced that the American Academy of Ophthalmology (AAO) has designated the Hydrus Microstent as “Level 1, Moderate Quality, Strong Recommendation.” The designation is the highest of any MIGS device in its 2020 Preferred Practice Pa
- One Year After FDA Approval, MiSight 1 Day Contact Lens Mainstreams Myopia Management in the U.S.https://modernod.com/news/one-year-after-fda-approval-misight-1-day-contact-lense280a8-mainstreams-myopia-management-in-the-u-s-e280a8e280a8/2478564/Today, CooperVision celebrates 1 year since MiSight 1 day became the first and only FDA approved contact lens for slowing the progression of myopia in children ages 8-12. The milestone and subsequent efforts have vaulted myopia management into mainstream eye care in the United States, including w
- Adaptilens Announces $1.6 Million in Seed Funding for Development of Accommodating IOLhttps://modernod.com/news/adaptilens-announces-1-6-million-in-seed-funding-for-development-of-accommodating-iol/2478536/Adaptilens announced a $1.6 million seed funding to fund the company’s development of an innovative accommodating IOL with the aim of allowing patients to live their lives free of glasses and contact lenses. The funding was led by Pillar VC with additional participat
- Zhaoke Ophthalmology Announces First Patient Completes 3-Year Enrollment in Phase 3 Myopia Trialhttps://modernod.com/news/zhaoke-ophthalmology-announced-first-patient-completes-3-year-enrollment-in-phase-3-myopia-trial/2478533/Zhaoke Ophthalmology Pharmaceutical has announced that the first patient has completed 3-year enrollment in the phase 3 CHAMP (Childhood Atropine for Myopia Progression) study carried out by its partner, Nevakar. The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound
- Hoya Surgical Optics Introduces On-Demand Platform Qube Pro Powered by Eyeflexahttps://modernod.com/news/hoya-surgical-optics-introduces-on-demand-platform-qube-pro-powered-by-eyeflexa/2478514/Hoya Surgical Optics obtained CE Mark for “Qube pro powered by eyeflexa,” a technology that can support both cataract and vitreoretinal surgery. Eyeflexa is a multi-upgrade platform designed to evolve with the changing needs of ophthalmic surgeons, according to a company news r